Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
M3554 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Dose Escalation: M3554 Monotherapy | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| M3554 | DRUG | M3554 will be administered at an escalated dose until Maximum tolerated dose (MTD) and/or a safe recommended Dose is determined in participants with STS (dose escalation A) and glioblastoma and IDH wildtype (dose escalation B). |
Inclusion Criteria: * Escalation A: participants with documented histopathological diagnosis of locally advanced or metastatic STS with unresectable disease that has progressed after at least one prior line of anthracycline-containing systemic therapy for the locally advanced/metastatic setting. * ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
M3554 is an investigational small molecule being developed for the treatment of advanced solid tumors. It is currently in Phase 1 clinical development, and the ongoing trial is studying its safety and efficacy in patients with advanced solid tumors.
M3554 is an antibody-drug conjugate (ADC) that targets GD2, a tumor-associated antigen. The drug is designed to deliver a cytotoxic payload to GD2-expressing tumor cells, potentially leading to their destruction.
M3554 is being developed by Merck & Company, Inc., a global biopharmaceutical company. Merck is conducting the Phase 1 clinical trial to evaluate the drug's safety and preliminary efficacy in patients with advanced solid tumors.
M3554 is in Phase 1 clinical development. The drug is investigational and has not yet been approved by regulatory authorities. The ongoing Phase 1 trial is actively recruiting participants to assess its safety, tolerability, and pharmacokinetics.
M3554 is being studied in a Phase 1 clinical trial with the identifier NCT06641908, titled "Anti-GD2 ADC M3554 in Advanced Solid Tumors." The trial is recruiting 52 participants across multiple countries, including the United States, Belgium, France, Japan, Switzerland, and the United Kingdom.
Yes, M3554 is an anti-GD2 antibody-drug conjugate. The clinical trial NCT06641908 specifically describes M3554 as an anti-GD2 ADC, indicating that the drug combines an antibody targeting GD2 with a cytotoxic agent for the treatment of advanced solid tumors.